Literature DB >> 7148514

Current status of Swedish hemophiliacs. I. A demographic survey.

S A Larsson, I M Nilsson, M Blombäck.   

Abstract

A comprehensive survey of the Swedish hemophilic population (hemophilia A and B) was undertaken in 1980. The total number of known hemophiliacs was 564. The ratio of hemophilia A to B was 4:1. The severe form constituted about 30% of each type. The incidence has remained fairly constant since 1957 and was 1.67 per year per 10,000 males born. The prevalence was 6.8 per 100,000 inhabitants. There was an increase in the prevalence in all counties but the increase varied considerably, 19-383%. The overall increase of hemophilia was 123%. Among mild cases the increase was 245%, whereas it was only 48% among the severe hemophiliacs. This skewness was attributed to better laboratory diagnoses and increased life expectancy. The proportion of mild cases increased from 35% in 1960 to 54% at the time of the present investigation. The situation was the reverse for the severe cases, a decrease from 45% to 30%. The mean and median ages among moderate and mild hemophiliacs deviated only little from the corresponding figure in the total population. Among severe cases, however, mean and median age were 8-13 years less than in the normal population.

Entities:  

Mesh:

Year:  1982        PMID: 7148514     DOI: 10.1111/j.0954-6820.1982.tb03200.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  9 in total

1.  Missense mutations and the magnitude of functional deficit: the example of factor IX.

Authors:  S S Sommer; E J Bowie; R P Ketterling; C D Bottema
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

Review 2.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

3.  Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene.

Authors:  D D Koeberl; C D Bottema; R P Ketterling; P J Bridge; D P Lillicrap; S S Sommer
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

4.  The use of blood components in the treatment of congenital coagulation disorders.

Authors:  I M Nilsson; S A Larsson; S E Bergentz
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

5.  The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene.

Authors:  C D Bottema; R P Ketterling; E Vielhaber; H S Yoon; B Gostout; D P Jacobson; A Shapiro; S S Sommer
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

6.  Sex ratio of the mutation frequencies in haemophilia A: estimation and meta-analysis.

Authors:  F R Rosendaal; A H Bröcker-Vriends; J C van Houwelingen; C Smit; I Varekamp; H van Dijck; T P Suurmeijer; J P Vandenbroucke; E Briët
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

7.  The rates and patterns of deletions in the human factor IX gene.

Authors:  R P Ketterling; E L Vielhaber; T J Lind; E C Thorland; S S Sommer
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

Review 8.  Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 9.  Prevention and Management of Bleeding Episodes in Children with Hemophilia.

Authors:  Rolf C R Ljung
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.